COPDNCT07208123
Mechanistic Studies of Chronic COPD Using Single-Cell Sequencing and Single-Cell Spatial Transcriptomics
An observational study of COPD, run by Tongji University at 1 site in China.
Trial summary
This study is an ambispective cohort study, the sample from patients were from both previously stored and freshly collected . The objective of this study is to investigate the molecular pathological changes underlying the development of chronic obstructive pulmonary disease (COPD). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- COPD
- How many people
- 150 participants
- Where
- 1 siteChina
- Study dates
- 30 Sep 2025to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: 150
Who may be able to join
- Receiving lung resection surgery at the hospital for any reason；
- Diagnosed with COPD according to the 2024 GOLD guidelines；
- Tissue samples that meet collection requirements and are either agreed to be collected or already preserved；
Who cannot join
- Improper preservation of pathological specimens, refusal to consent to sample collection, or incomplete clinical information；
- Combined with other factors causing obstructive airflow limitation;
- Diagnosed with asthma according to the GINA 2023 guidelines and with a history of asthma exacerbations within the past year;
- Combined with Advanced lung cancer;
- Receiving systemic immunosuppressive medications such as anti-rejection drugs;
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200444
Tang Jiang, Dr, +86 021-86383707, 52290946015@stu.ecnu.edu.cn
About this study
Official title: A Bidirectional Cohort Study of Single-Cell Sequencing and Single-Cell Spatial Transcriptomics in Chronic COPD
This study is an ambispective cohort study, the sample from patients were from both previously stored and freshly collected . The objective of this study is to investigate the molecular pathological changes underlying the development of chronic obstructive pulmonary disease (COPD). We will use single cell sequencing technology to analyze lung tissue samples from patients who underwent lung resection, with lung tissue from patients without COPD serving as controls. This research aims to provide insights into the pathogenesis of COPD.
- Conditions
- COPD
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| COPD group | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Transcriptomic profile analysis of lung tissues
Measured: until end of surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2025
- Study start30 Sep 2025 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COPDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tongji University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fang Chen, Tongji University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07208123
- Sponsor's protocol ID
- HSCRNACOPD-001
- Status last verified
- Sep 2025
- First submitted
- 27 Sep 2025
- Last updated
- 6 Oct 2025
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Bidirectional Cohort Study of Single-Cell Sequencing and Single-Cell Spatial Transcriptomics in Chronic COPD
- ClinicalTrials.gov ID
- NCT07208123
- Acronym / sponsor ID
- HSCRNACOPD-001
- Conditions
- COPD
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Tongji UniversityUniversity, hospital or other
- Study start
- 30 Sep 2025 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 6 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is an ambispective cohort study, the sample from patients were from both previously stored and freshly collected . The objective of this study is to investigate the molecular pathological changes underlying the development of chronic obstructive pulmonary disease (COPD). We will use single cell sequencing technology to analyze lung tissue samples from patients who underwent lung resection, with lung tissue from patients without COPD serving as controls. This research aims to provide insights into the pathogenesis of COPD.
Study design
- Observational model
- Other
- Time perspective
- Other
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| COPD group | – | – |
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- 150
Key inclusion criteria (3 listed)
- Receiving lung resection surgery at the hospital for any reason；
- Diagnosed with COPD according to the 2024 GOLD guidelines；
- Tissue samples that meet collection requirements and are either agreed to be collected or already preserved；
Key exclusion criteria (5 listed)
- Improper preservation of pathological specimens, refusal to consent to sample collection, or incomplete clinical information；
- Combined with other factors causing obstructive airflow limitation;
- Diagnosed with asthma according to the GINA 2023 guidelines and with a history of asthma exacerbations within the past year;
- Combined with Advanced lung cancer;
- Receiving systemic immunosuppressive medications such as anti-rejection drugs;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Transcriptomic profile analysis of lung tissues
Time frame: until end of surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2025.
Related trials for COPD
Recruiting
Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in Canada
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
Not yet recruitingPhase 2
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Not yet recruitingPhase 3
Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)
Chronic Obstructive Pulmonary Disease
RecruitingObservational study
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Chronic Obstructive Pulmonary Disease (COPD), Smoking
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COPD, run by Tongji University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Feng Xinyu, Dr (86-17621694653, 52290946015@stu.ecnu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Transcriptomic profile analysis of lung tissues (time frame: until end of surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2025.